NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Ophthalmology


Return to Library

Free Ophthalmology Articles


Study results from Oakland University update understanding of glaucoma



2009 AUG 3 - (NewsRx.com) -- In this recent report published in the Journal of Glaucoma, researchers in the United States conducted a study "TO compare 2 vision-specific functional status measures to each other and to clinical parameters in the Collaborative Initial Glaucoma Treatment Study (CIGTS). CIGTS participants completed the Visual Activities Questionnaire (VAQ) and the National Eye Institute-Visual Function Questionnaire (NEI-VFQ) and were tested for visual field (VF) and visual acuity (VA)."

"In all, 426 Subjects contributed the VAQ and NEI-VFQ scores at 54 months. Pearson correlations were used to assess associations. The VAQ subscales (range, 0 to 100) that assessed light-dark adaptation (mean = 66.1), glare disability (66.4), and acuity/spatial vision (67.7) indicated vision-related functions that CIGTS participants found most difficult. On the NEI-VFQ, subjects reported high levels of visual functioning, with mean:90 (out of 100) on the total score and in 9 of 12 subscales. General vision (mean = 82.6) received the lowest subscale score. Two subscales common to both questionnaires were highly correlated: VA (r = 0.68) and peripheral vision (r = 0.77) (both P< 0.0001). Correlations between participants' perceptions and clinical measures of visual function Were in the expected direction, but weaker. Stronger associations were found between clinical measures and the NEI-VFQ than the VAQ. Better eye VF and worse eye VA had the highest number of significant correlations with Subjects' perceptions of their visual function. Increasing VF loss was associated with a significant decrease in the overall and peripheral vision subscale scores from both questionnaires, and also several other subscales. CIGTS patients reported excellent visual function on both the NEI-VFQ and VAQ," wrote P.A. Wren and colleagues, Oakland University.

The researchers concluded: "These findings will help researchers interested in assessing patients' perceptions of their visual function make an informed selection when choosing between the VAQ and the NEI-VFQ."

Wren and colleagues published their study in the Journal of Glaucoma (Contrasting the Use of 2 Vision-specific Quality of Life Questionnaires in Subjects With Open-angle Glaucoma. Journal of Glaucoma, 2009;18(5):403-411).

For additional information, contact P.A. Wren, Oakland University, School Health Science, Dept. of Wellness Health Promotion & Injury Prevention, Rochester, MI 48309, USA.

The publisher's contact information for the Journal of Glaucoma is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.

Keywords: United States, Rochester, Genetics, Glaucoma, Open-Angle Glaucoma, Ophthalmology, Quality of Life, Oakland University.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login